GENE ONLINE|News &
iPark Institute Unveils AI-Driven “iDCP” to Connect Asian Life Science Innovators with Global Investors
iPark Institute has announced the launch of the “iPark Digital Community Platform (iDCP)”, a digital matching platform utilizing AI to bridge the gap between Asian start-ups or academic institutions and global investors and pharmaceutical companies. (Image: Shonan iPark)
In a move designed to dismantle barriers between Asian innovation and the global market, iPark Institute Co., Ltd. has announced the upcoming launch of the iPark Digital Community Platform (iDCP). Scheduled for official release on March 1, 2026, this digital matching platform utilizes artificial intelligence (AI) to bridge the gap between Asian biopharma start-ups or academic institutions and global investors and pharmaceutical companies.
Unlocking the “Black Box” of Asian Innovation
The development of iDCP addresses a significant disparity in the global life sciences market. While technologies from Europe and the US enjoy widespread visibility, outstanding innovations originating from Asian start-ups and academia are often not recognized by global investors and pharmaceutical companies. This lack of visibility has created an information “black box” that hinders potential collaborations.
For Asian innovators, the barriers to entry are multifaceted. Start-ups and academic institutions often struggle with uncertainty regarding what information global venture capitalists (VCs) and corporations are seeking. Additionally, they face significant burdens regarding multilingual support and information preparation, creating barriers to building global networks. In order to structurally address these challenges and accelerate encounters between global investors and innovative technologies, iPark Institute created iDCP with the core concept of “unlocking Asian technologies and information.”
Key Features: AI-Driven Structuring and Matching
The iDCP platform distinguishes itself through automation and security features designed to streamline the due diligence and scouting process:
- AI-Driven Matching: The platform utilizes AI to automatically match the technological information of startups and academia with the specific areas of interest defined by VCs and pharmaceutical companies.
- Automated Information Optimization: Using multilingual AI, iDCP automatically structures and optimizes technology information entered by innovators into formats specifically tailored for investors and corporate partners.
- Secure Environment: To facilitate deeper discussions, the platform allows users to access highly reliable confidential information following the execution of Non-Disclosure Agreements (NDAs) directly on the iDCP platform.
Launch Campaign and Early Access
Ahead of the official March 1, 2026 release, iPark Institute has opened pre-registration to encourage early adoption. The institute is offering an early-access campaign where start-up companies, academic institutions, investors, and pharmaceutical companies can utilize the platform free of charge until the end of September 2026. Industry stakeholders interested in leveraging this new global gateway are encouraged to register via the official iDCP website.
About iPark Institute and Shonan iPark
iPark Institute Co., Ltd. is the dedicated management and operations company for Shonan Health Innovation Park (Shonan iPark), Japan’s first pharma-led science park which was established in April 2018. The institute, as a Takeda spinoff, began operations in April 2023 to transition the park into a neutral, independent ecosystem for life science research, investment and innovation.
Major shareholders of the institute include the Industrial & Infrastructure Fund Investment Corporation (IIF), Takeda Pharmaceutical Company Limited, and Mitsubishi Corporation. Under this independent management structure, the organization aims to facilitate the convergence of industry, government, and academia across various industries and scales to accelerate health innovation.
The ecosystem at Shonan iPark has expanded significantly beyond traditional pharmaceuticals. As of January 2026, it comprises approximately 220 companies and over 3,500 individuals. The diverse tenant base includes pharmaceutical companies, next-generation medicine developers, cellular agriculture companies, AI firms, and government organizations.
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Dana‑Farber Researchers Develop AI Assistant to Help Oncologists Navigate Precision Cancer Treatments
2026-01-29
JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb
2026-01-15
